Patents by Inventor Thale Jarvis

Thale Jarvis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enzymatic nucleic acids that cleave C-fos
    Patent number: 6103890
    Abstract: Enzymatic nucleic acid molecules which cleave c-fos RNA.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: August 15, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Thale Jarvis, James A. McSwiggen, Dan T. Stinchcomb
  • Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
    Patent number: 5998203
    Abstract: An enzymatic nucleic acid molecule comprising a 5'- and/or a 3'-cap structure, wherein said structure is not a 5'-5'-linked inverted nucleotide or a 3'-3'-linked inverted nucleotide.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: December 7, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Jasenka Matulic-Adamic, Leonid Beigelman, Alexander Karpeisky, Thale Jarvis, Nassim Usman, Anthony DiRenzo, Francine Wincott
  • B7-1 targeted ribozymes
    Patent number: 5877021
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1.
    Type: Grant
    Filed: January 12, 1996
    Date of Patent: March 2, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • C-myb ribozymes having 2'-5'-linked adenylate residues
    Patent number: 5817796
    Abstract: Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 6, 1998
    Inventors: Dan T. Stinchcomb, Kenneth Draper, James McSwiggen, Thale Jarvis
  • C-myb targeted ribozymes
    Patent number: 5646042
    Abstract: Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: July 8, 1997
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth Draper, James McSwiggen, Thale Jarvis